A chemical engineer at Cambridge University has devised a simple nipple shield that prevents HIV transmission Pharmaceutical producer Merck and Co., Inc. recently announced that it will begin studying one of its HIV drugs, raltegravir (Isentress), for use in once-daily dosing.
Raltegravir was the first, and currently the only, integrase inhibitor available to the pubic. Integrase inhibitors, a developing class of medications used to target HIV, work in collaboration with other HIV drugs to impact the replication of the virus. Specifically, these drugs intervene where HIV actually integrates itself into human DNA.
Currently, raltegravir is prescribed twice-daily as a part of an antiretroviral regimen. This new study, referred to as QDMARK, will compare this dosage with a once-daily dosage, with emtricitabtine and tenofovir (Truvada) prescribed as the additional necessary components of therapy for participants. The study will enroll 750 patients at 94 centers in 21 countries.
Patients interested in taking part in the QDMARK clinical trial are encouraged to speak with their physician. For more information, please visit www.benchmrk.com and click on QDMRK.